Palforzia clinical trials
Also written Peanut protein and DBV712.
How each study uses Palforzia is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 31 Jan 2020 · Palforzia · BLA 125696 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 9
DBV Technologies (5) · Auburn University (3) · Chinese University of Hong Kong (1) · Texas A&M University (1) · Scott Sicherer (1) · Stanford University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of North Carolina, Chapel Hill (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Palforzia, phase 3 first.
- Nov 2026Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)Phase 3 · DBV Technologies
Studies
Open first, then newest update. How each study uses Palforzia is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young ChildrenCompletedPhase 3DBV TechnologiesNCT03859700Written as DBV712 250 mcg
- Peanut Sip Feeding ProtocolCompletedNot applicableTexas A&M UniversityNCT06693544Written as Peanut protein
- Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)Active, not recruitingPhase 3DBV TechnologiesNCT07003919Written as DBV712 250 mcg
- Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of AgeActive, not recruitingPhase 3DBV TechnologiesNCT05741476Written as DBV712
- Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut AllergyCompletedPhase 3DBV TechnologiesNCT02636699Written as Viaskin Peanut 250mcg
- Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut AllergyCompletedPhase 2Scott SichererNCT03907397Written as Peanut Protein
- A Randomized, Controlled Trial of Probiotic and Peanut Oral Immunotherapy (PPOIT) in Inducing Tolerance in Hong Kong Children With Peanut Allergy Compared With Oral Immunotherapy (OIT) Alone and With PlaceboActive, not recruitingNot applicableChinese University of Hong KongNCT05165329Written as PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations
- Peanut Protein Supplementation to Prevent Muscle Atrophy and Improve Recovery Following Total Knee ArthroplastyTerminatedNot applicableAuburn UniversityNCT04294563Written as Peanut Protein Powder
- Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Young AdultsCompletedNot applicableAuburn UniversityNCT04707963Written as Peanut protein powder
- Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older AdultsCompletedNot applicableAuburn UniversityNCT04015479Written as Peanut Protein Powder
- The Peanut Oral Immunotherapy Study: Safety, Efficacy and DiscoveryCompletedPhase 2Stanford UniversityNCT02103270Written as Peanut Protein 300 mg
- A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic SubjectsCompletedPhase 1DBV TechnologiesNCT03352726Written as DBV712 IHRP
- Peanut Epicutaneous Phase II Immunotherapy Clinical TrialCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01904604Written as Low-dose DBV712 Viaskin® Patch
- Oral Peanut Immunotherapy for Peanut Allergic PatientsCompletedEarly Phase 1University of North Carolina, Chapel HillNCT01891136Written as Peanut protein
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Codes
What other systems call Palforzia · ClinicalTrials.gg INT002132
- MeSH (NLM) C000731750PalforziaOne source NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731750 | Palforzia | One source NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.